BNPCV APCCB 20041 BIOLOGICAL VARIATION FOR N-TERMINAL PRO-BNP Jones GRD 1, Bennett A 2,3, Boscato L 1, Macdonald P 2, Brien J 3. Departments of Chemical.

Slides:



Advertisements
Similar presentations
Ninewells Hospital & Medical School
Advertisements

AACB NSW/ACT QC Subcommittee TnT hs Survey Results Methods Results Introduction Persephone Giannopoulos¹ and representatives of the AACB NSW/ACT QC Subcommittee.
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
Biological Variation Data: Time for Development of Standards? Dr William A Bartlett, On behalf of the Biological Variation Working Group, European Federation.
The Value of a Chest X-Ray in Diagnosing Pneumonia in SIRS Patients Lacking Respiratory Symptoms in York Hospital’s Emergency Department Michelle Lynch.
High Sensitivity Troponin
L MACKAY, N CRINIS, Q LAM, R SCOTT
MHA APCCB A SERUM INDEX FOR METHAEMALBUMIN: THE M-INDEX GRD Jones, M Roser, B Zworestine Department of Chemical Pathology, St Vincents Hospital,
APCCB ERROR REDUCTION WITH WEB-BASED CLINICAL CALCULATORS LINKED TO PATIENT RESULTS. Jones GRD and Tinker E Departments of Chemical Pathology and.
Quality Assurance.
BOHB APCCB LABORATORY USE OF THE ABBOTT MEDISENSE METER FOR BETA-HYDROXYBUTYRATE MEASUREMENT. GRD Jones, A Screnci, P Graham Chemical Pathology,
Chemometrics Method comparison
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Quality Assurance.
Quality Assessment 2 Quality Control.
APCCB AVERAGE OF DELTA – A NEW CONCEPT IN QUALITY CONTROL GRD Jones Department of Chemical Pathology, St Vincents Hospital, Sydney, Australia.
1. Dr. Adel M. Assiri Faculty of Medicine Department of Biochemistry Umm Al-Qura University.
PG-Seph. APCCB IDENTIFICATION OF MACRO- PROLACTIN WITH PROTEIN-G SEPHAROSE Jones GRD, Giannopoulos P. Departments of Chemical Pathology, St Vincent’s.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
AACB ASM 2003 THE POWER OF ERROR DETECTION OF WESTGARD MULTI-RULES: A RE-EVALUATION Graham Jones Department of Chemical Pathology St Vincent’s Hospital,
Journal Club Influence of Glycosylation on Diagnostic and Prognostic Accuracy of N-Terminal Pro–B-type Natriuretic Peptide in Acute Dyspnea: Data from.
Analytical Goals. Valid data are essential in making medical decisions, the most important concepts used in judging analytical performance :- 1)Analytical.
A High Prevalence of Vitamin D Inadequacy in a Minimal Trauma Fracture Population A High Prevalence of Vitamin D Inadequacy in a Minimal Trauma Fracture.
Influence of Analytical Bias and Imprecision on Guideline-Driven Medical Decision Limits Per Hyltoft Petersen Hyltoft Petersen P, Klee GG. Influence of.
Management of Hypertensive Emergencies. New paradigm in treatment of acute hypertension Acute vascular injury has chronic sequelae Prevention of exaggerated.
Evaluation of Beckton-Dickinson PST II and SST II Blood Collection Tubes P Graham, B Martin, M Roser, G Jones Department of Chemical Pathology, St Vincent’s.
Timeliness of Cancer Registry Reporting Ali Johnson, CTR Vermont Cancer Registry Vermont Explor Annual Data Meeting May 1, 2006.
Specific Aim 1: Determine the impact of psychiatric disorders on the hospital length of stay (LOS) in pediatric patients diagnosed with SCD admitted for.
Prof. of Clinical Chemistry, Mansoura University.
Quality Control Lecture 5
Stability APACB MATRIX AND STABILITY STUDY: PTH, INSULIN AND C-PEPTIDE Boscato L, Bayoun R and Jones GRD Chemical Pathology, St Vincent’s Hospital,
G Jones, M Roser Department of Chemical Pathology
Interferences - are some methods better than others? Graham Jones Department of Chemical Pathology St Vincent’s Hospital, Sydney.
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
SALIVARY, PROTEIN UNBOUND AND TOTAL PLASMA CONC OF RIFAMPICIN HADIJA H SEMVUA 11/12/2015KCRI_PhD SYMPOSIUM
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
Statistics & graphics for the laboratory 25 Biological variation Introduction Estimation (ANOVA application) Index-of-individuality Comparison of a result.
Long-term functional deficiencies of ICU-acquired weakness: a prospective study I Patsaki, G Sidiras, V Gerovasili, A Kouvarakos, E Polimerou, G Mitsiou,
Hospital Based Surveillance to Estimate the Burden of Rotavirus Gastroenteritis Among European Children Younger than 5 Years of Age Johannes Foster, Alfredo.
VERIFICATION OF REFERENCE INTERVALS GIAN LUCA SALVAGNO, MD, PhD University of Verona, Italy.
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
Quality Control Internal QC External QC. -Monitors a test's method precision and analytical bias. -Preparation of quality control samples and their interpretation.
L ABORATORY Q UALITY C ONTROL. INTRODUCTION _A major role of the clinical laboratory is the measurement of substances in body fluids or tissues for the.
Lecturer: Bahiya Osrah.  It is a chronic disease associated with hyperglycemia (increased blood glucose level) & glucourea (presence of glucose in urine)
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Troponin By Julie Moore C Dt204/2.
WELCOME BNP testing. Aims of this education package Better understanding of what BNP testing is How to appropriately use the test How to request the.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Prognostic Value of N-Terminal Pro–B-Type Natriuretic.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Readmissions After Carotid Artery Revascularization.
Table 1. Methodological Evaluation of Observational Research (MORE) – observational studies of incidence or prevalence of chronic diseases Tatyana Shamliyan.
Pharmacist Impact on Patient Mortality and Advanced Cardiac Life Support Guideline Compliance During In-Hospital Cardiac Arrest Joseph Cavanaugh, PharmD.
Mahmoud Farhoud, MD 1,2, Paul Ndunda, MD 2,K James Kallail, PhD 2, Hussam Farhoud, MD, FACC 3 1 University of Central Florida College of Medicine, 2 University.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.
Acute Renal Failure in Aneurysmal Subarachnoid Hemorrhage: Nationwide Analysis of Hospitalizations in the United States Kavelin Rumalla 1, Adithi Y. Reddy.
Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:
Biomarkers that “guide” therapy
Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.
Josiane Arnaud1, Jean-Philippe Weber2,
Quality of Electronic Emergency Department Data: How Good Are They?
PCI related in-hospital mortality based on race and gender in the USA
Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018
Nat. Rev. Cardiol. doi: /nrcardio
An example of the Lancet
Introduction To Medical Technology
Quality Control Lecture 3
▪Internal quality control:
Coiffier B et al. Proc ASH 2011;Abstract 265.
Presentation transcript:

BNPCV APCCB BIOLOGICAL VARIATION FOR N-TERMINAL PRO-BNP Jones GRD 1, Bennett A 2,3, Boscato L 1, Macdonald P 2, Brien J 3. Departments of Chemical Pathology 1, Cardiology 2 and Pharmacy 3, St Vincent’s Hospital, Sydney, Australia.

BNPCV APCCB Background N-terminal proBNP (proBNP) is a plasma biomarker approved for use in the diagnosis and monitoring of patients with congestive cardiac failure. Within-individual variation (CVwi) is an important parameter for assessing required analytical precision and calculating critical changes. This data is currently available for proBNP only in healthy individuals 1. –Average CVwi = 36% In this study we evaluate the within-individual biological variation of proBNP in patients with stable heart failure.

BNPCV APCCB Methods 1: Patients Patients with symptomatic heart failure were identified during hospital admission. Samples for proBNP were collected 2 weeks, 3 months and 6 months after discharge. Patients were considered to have stable heart failure if, during 12 months from discharge, they: 1. Remained alive. 2. Did not undergo cardiac transplant. 3. Were not re-admitted with a diagnosis of heart failure. 4. Did not change their number of cardiac medications in 6 months. A looser definition of stable heart failure was assessed –Criteria 1 - 3, but allowing a single change in the number of cardiac medications during 6 months.

BNPCV APCCB Methods 2: Measurements Samples were collected into K 2 EDTA tubes, centrifuged and plasma stored at -20 degrees until analysis. proBNP was measured on an Elecsys 2010 analyser Within-run CV was < 2% and total CV< 6% at all levels tested 2. All samples for a single patient were analysed in the same analytical run.

BNPCV APCCB Patient Demographics After initial exclusions, 17 patients were considered to have stable heart failure (out of a total of 102). Average age of included patients: 76 (range 62-91) The median of all proBNP results was 2280 ng/L (range: 380 to 10,440 ng/L) These results are consistent with the clinical diagnoses of NHYA class 2 or 3 heart failure. CVs were calculated from the 3 data points for each patient. Data from 2 patients was excluded as statistical outliers. (CV>1 SD from next result) –One patient known not to be compliant with medication. –One patient with a single result 7 x other two results.

BNPCV APCCB Within-Person Variation Figure. Changes in proBNP over time in 17 patients with stable heart failure. The two patients with data removed due to high CVs are shown in red. proBNP (ng/L)

BNPCV APCCB Results Stable Heart Failure (2 outliers excluded) - 15 patients: –Average proBNP was 2280 pg/mL –Average within-person CV was 23%, range: 3 – 44% – (excluded CVs were 66% and 119%) Stable Heart Failure (no outlier exclusion) - 17 patients: –Average proBNP was 3074 pg/mL –Average within-person CV was 32% (range: 3 – 119%) Stable Heart Failure (1 medication change) - 34 patients: –Average proBNP result 2447 pg/mL –The average within-person CV was 36% (range %)

BNPCV APCCB Interpretation With the stated between-assay imprecision of 6% and the critical difference at the 95% level for each estimate of CVwi are as follows: –CVwi of 24% - CD is a 68% change in concentration. –CVwi of 36% - CD is 100% change in concentration. Using the Roche assay a doubling or halving of proBNP results in a patient with heart failure is highly likely to indicate a significant change in proBNP concentration.. The Roche proBNP assay is performing better than the optimal precision level –Optimal total precision < 0.25 x CVwi. 3 –Elecsys total precision < 6%; target: 6 - 9%

BNPCV APCCB Discussion Within-person biological variation has been extensively studied for many analytes in healthy people. Fewer studies have been performed on people with disease. A major difficulty is the definition of stable disease. We have obtained a range of results for average CVwi depending on the definition of “stable disease”. Our range of CVwi overlaps that reported in healthy individuals 1. The small number of samples per patient may account for the wide ranges seen. Log transformation of the data allows better parametric description, but may be less useful in clinical practice.

BNPCV APCCB Conclusions Using the tightest definition of stable heart failure the average within-individual biological variation has a CV of 24%, although higher values may be supported by the data. Depending on definition of stable heart failure, the critical change value is between 70% and 100%. The Roche assay clearly meets precision targets based on biological variation. REFERENCES 1. Wu A et al. Am J Cardiol Jones GRD, Boscato L, Schneider H-G, Clin Biochem Rev 2002 (abstract). 3. Fraser CG et al. Ann Clin Biochem 1997;34:8-12. ACKNOWLEDGEMENT We acknowledge Roche Diagnostics Australia for reagents and equipment.